Search results
Results from the WOW.Com Content Network
Beta blockers vary in their lipophilicity (fat solubility) and in turn in their ability to cross the blood–brain barrier and exert effects in the central nervous system. [76] Beta blockers with greater blood–brain barrier permeability can have both neuropsychiatric therapeutic benefits and side effects, as well as adverse cognitive effects ...
Anti-adrenergics: See also alpha blocker and beta blocker. Clonidine (α-receptor agonist, α 2 > α 1, giving negative feedback) Methyldopa (α 2 agonist, giving negative feedback) Propranolol (β-receptor antagonist) Metoprolol (β-receptor antagonist) Atenolol (β 1 antagonist) Prazosin (α 1 antagonist) Oxymetazoline (partial α2 adrenergic ...
Toxicity of beta-1 blocker will contribute to symptoms including bradycardia, hypotension, due to its extensive blockage of beta-1 receptor. [5] Moreover, overdose of beta-1 blocker may lead to the loss of their selectivity and bind to beta-2 receptor , causing bronchopulmonary symptoms . [ 5 ]
Beta adrenergic agonists or beta agonists are medications that relax muscles of the airways, causing widening of the airways and resulting in easier breathing. [1] They are a class of sympathomimetic agents, each acting upon the beta adrenoceptors . [ 2 ]
Antinicotinic agents are classified into ganglionic blockers and neuromuscular blockers. Ganglionic blockers are of little clinical use as they act at all autonomic ganglions. [1] [2] They act by: Interfering acetylcholine release; Prolonged depolarization (depolarisation block), i.e. stimulation then block stimulation
Clenbuterol is a growth-promoting drug in the β agonist class of compounds. It is not licensed for use in China, [22] the United States, [21] or the EU [23] for food-producing animals, but some countries have approved it for animals not used for food, and a few countries have approved it for therapeutic uses in food-producing animals.
Additionally, beta 1 blockers can affect beta 2 receptors, particularly at high doses, and hence should not be administered to patients with peripheral vascular disease or diabetes mellitus as they may cause vasoconstriction or a delayed hypoglycaemic response, respectively. [4]
Figure 1: The chemical structure of dichloroisoprenaline or dichloroisoproterenol (), abbreviated DCI — the first β-blocker to be developed. β adrenergic receptor antagonists (also called beta-blockers or β-blockers) were initially developed in the 1960s, for the treatment of angina pectoris but are now also used for hypertension, congestive heart failure and certain arrhythmias. [1]